Clinical trials: Dementia Disorder, open to volunteers
Dementias, Neurodegenerative Dementia
In-depth Analysis of Cholesterol Metabolism and Related Biomarkers in the Pathogenesis and Progression of the Disease in Neurodegenerative Dementias
The aim of the study is to evaluate the role of cholesterol in the pathogenesis of neurodegenerative dementias. Hypercholesterolemia is a known risk factor for Alzheimer disease (AD), and oxysterols, the principal cholesterol…
- Trial name
- RF-2021-123742 (NCT07207486)
- Where
- 2 sites in Italy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Multiple Sclerosis, Parkinson Disease
Biomarkers of Synaptic Damage in Multiple Sclerosis
A prospective and retrospective cohort study of about five years will be performed on blood and cerebrospinal fluid samples taken for diagnostic reasons from recruited patients within the Neuromed Neurology Unit.
- Conditions
- Multiple Sclerosis, Parkinson Disease, Amyotrophic Lateral Sclerosis, Alzheimer Disease
- Trial name
- NCT03217396
- Testing
- lumbar puncture
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Neuromed IRCCS
Lewy Body Dementia (LBD), Alzheimer Dementia (AD)
Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia and Related Dementias
This study is being done to research the usefulness of PET/CT imaging for measuring brain inflammation and its relation to Alzheimer's Disease Dementia and related dementias.
- Trial name
- NCT04786223
- Testing
- C-11 ER-176, Blood Test
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Val Lowe
Depressive Sympotoms
Effects of a Salutogenic Strength-based Social Robot-assisted Intervention on the Depressive Symptoms and Sense of Coherence of Family Caregivers of Persons With Dementia
Family caregivers of persons with dementia (PwD) are well known to be "invisible patients." Existing studies have suggested that sense of coherence (SOC), a core inner strength, could be a protective factor against depression…
- Trial name
- social robot (NCT07531082)
- Testing
- A salutogenic strength-based, robot-assisted intervention, Control
- Volunteers
- 148 people
- Sponsor
- The Hong Kong Polytechnic University
Alzheimer Disease, Dementia
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
This study seeks to improve clinical outcomes for an important, growing, and vulnerable population-nursing home residents with Alzheimer's disease or related dementias-by testing an evidence-based intervention to improve these…
- Conditions
- Alzheimer Disease, Dementia, Sleep Disorder, Sleep Disturbance
- Trial name
- 40Winks (NCT05820919)
- Testing
- LOCK Sleep Program, No intervention (control period/baseline data collection)
- Where
- 3 sites in United States
- Volunteers
- 456 people
- Sponsor
- University of Alabama, Tuscaloosa
Family Caregivers, Dementia
Financial Counseling for Dementia Family Caregivers in Early and Middle Adulthood
The goal of this National Institutes of Health (NIH) Stage 1a study is to develop and pilot test a research- and community-informed financial counseling and advocacy (FCA) intervention for dementia family caregivers in early and…
- Conditions
- Family Caregivers, Dementia, Financial Wellbeing, Financial Coaching
- Trial name
- FCA 4 FC-EAMA (NCT07681401)
- Testing
- Financial Counseling and Advocacy
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Utah
Alzheimer's Disease
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
The purpose of this study is to: Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after…
- Trial name
- NCT07214727
- Testing
- ALN-5288
- Where
- 13 sites in Canada, Netherlands and 2 more
- Volunteers
- 50 people
- Sponsor
- Alnylam Pharmaceuticals
Alzheimer Disease
Brain Connectivity Marker for Alzheimer's Disease
The main purpose of this project is to establish whether changes in brain connectivity can be used to predict the development of Alzheimer's disease (AD).
- Trial name
- BRAINCONN (NCT06874231)
- Testing
- Neuroimaging
- Where
- Sweden
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Eldery People, Cognitive Decline
Optimizing CNS DHA Delivery in Elderly Adults at Risk for Dementia
The purpose of this placebo-controlled trial is to compare the effects of 24-weeks supplementation with LPC-DHA and TAG-DHA on cerebrospinal fluid and blood DHA levels, as well as biomarkers of central neurodegenerative and…
- Conditions
- Eldery People, Cognitive Decline, Memory Decline, DHA CNS Delivery
- Trial name
- NCT06933095
- Testing
- LPC-EPA+DHA capsules containing omega-3 fatty acids EPA and DHA esterified to lysophosphatidylcholine (LPC-EPA+DHA)(Trade name: Lysoveta)
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- University of Cincinnati
Dementia Patients Care, Emotional
Emotional Care Competency Scale for Dementia: Development and Correlations With Knowledge, Attitudes, and Confidence
This study aims to develop an "Emotional Care Competency Scale for Dementia" targeting long-term care professionals and to explore the relationship between caregivers' emotional care competency and their knowledge, attitudes, and…
- Trial name
- NCT06773741
- Volunteers
- 200 people
- Sponsor
- Chang Gung University of Science and Technology
Non-Hodgkin Lymphoma, B-cell
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
The goal of the study is to assess the safety and anti-lymphoma activity of MEN1703 (Dapolsertib hydrochloride) when given as a single-agent or combined with glofitamab to patients with relapsed/refractory (R/R) aggressive B-cell…
- Trial name
- JASPIS-01 (NCT06534437)
- Testing
- MEN1703, Glofitamab
- Where
- 35 sites in France, Poland and 2 more
- Volunteers
- 178 people
- Sponsor
- Ryvu Therapeutics SA
Alzheimers Disease
A Postmarketing Study of LEQEMBI in United Kingdom (UK) Participants With Alzheimer's Disease (AD)
The primary purpose of the study is to describe the incidence and severity of known adverse events (AEs), including Amyloid-Related Imaging Abnormalities Oedema/Effusion (ARIA-E), Amyloid-Related Imaging…
- Trial name
- NCT07781345
- Testing
- No Intervention
- Where
- 3 sites in United Kingdom
- Volunteers
- 400 people
- Sponsor
- Eisai Limited
Huntington Disease
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
The main goal of this study is to evaluate the safety, tolerability, and preliminary efficacy of SPK-10001 in participants with Huntington's Disease.
- Trial name
- NCT06826612
- Testing
- SPK-10001
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- Hoffmann-La Roche
Alzheimer Disease (AD)
Alzheimer's Disease Treated With Vagus Nerve Stimulation
The goal of this clinical trial is to evaluate the safety and efficacy of vagus nerve stimulation (VNS) for treating Alzheimer's disease (AD) in patients aged 50-80 years with mild cognitive impairment to moderate Alzheimer's…
- Trial name
- Advant (NCT06923007)
- Testing
- Vagus Nerve Stimulation
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Beijing Municipal Administration of Hospitals
Dementia, tDCS
The Efficacy of HD-tDCS-Augmented Step Training in Older Adults With Mild Dementia
Falls and mobility decline are major health concerns among older adults with dementia, often linked to deterioration in executive function and cognitive-motor control.
- Conditions
- Dementia, tDCS, Physical Exercise, Neuromodulation
- Trial name
- NCT07841145
- Testing
- Step training, active HD-tDCS
- Where
- Hong Kong
- Volunteers
- 68 people
- Sponsor
- The Hong Kong Polytechnic University
REM Sleep Behavior Disorder, Parkinson Disease
North American Prodromal Synucleinopathy Consortium Stage 2
This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
- Conditions
- REM Sleep Behavior Disorder, Parkinson Disease, Lewy Body Dementia, Dementia With Lewy Bodies
- Trial name
- NAPS2 (NCT05826457)
- Where
- 9 sites in United States, Canada
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB)
Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies
Progressive supranuclear palsy (PSP), mild cognitive impairment with Lewy bodies (MCI-LB), and Dementia with Lewy Bodies (DLB) are severe neurodegenerative diseases that cause significant motor impairment impacting daily…
- Conditions
- Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB), PSP, Lewy Body Dementia (LBD)
- Trial name
- NCT07240805
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- BioSensics
Parkinson Disease
Amyloid Monoclonal Antibody Treatment in PD Patients With Coexistent AD Pathology
This study aimed to determine the efficacy of amyloid clearance of lecanemab in patients with Parkinson's disease (PD) with amyloid co-pathology.
- Trial name
- NCT07544953
- Testing
- Lecanemab, Lecanemab non-administration group
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Yonsei University
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Trial name
- MINDSET 2 (NCT06976203)
- Testing
- KarXT, KarX-EC
- Where
- 128 sites in United States, Argentina and 15 more
- Volunteers
- 586 people
- Sponsor
- Bristol-Myers Squibb
Dementia
AI4HOPE Pilot Study 1 Digital Toolkit Assessment
The pilot study will develop and test a standardized assessment toolkit that will provide conclusive information with a tolerable burden for cognitively impaired patients with dementia.
- Trial name
- AI4HOPE1 (NCT06289322)
- Testing
- Digital toolkit for assessment
- Volunteers
- 150 people
- Sponsor
- University of Bonn
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.